Network Ad
💻 Tech Wire — Technology & startup news Explore
Loading...
111

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk. Researchers found that just one year of treatment with the immune-targeting drug abatacept delayed the onset of rheumatoid arthritis by up to four years, with benefits lasting long after treatment ended.

Be respectful and constructive. Comments are moderated.

No comments yet.